Peginesatide
- Generic Name
- Peginesatide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 913976-27-9
- Unique Ingredient Identifier
- JX56W9N61Q
- Background
Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and Ξ²-alanine. FDA approved March 27, 2012.
- Indication
Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis
- Associated Conditions
- -
- Associated Therapies
- -
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)
- Conditions
- Interventions
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2012-06-29
- Lead Sponsor
- Affymax
- Target Recruit Count
- 114
- Registration Number
- NCT00453973
- Locations
- π¬π§
Research Facility, Swansea, United Kingdom
Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2012-06-29
- Lead Sponsor
- Affymax
- Target Recruit Count
- 91
- Registration Number
- NCT00434330
- Locations
- π¬π§
Research Facility, London, United Kingdom
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2012-06-29
- Lead Sponsor
- Affymax
- Target Recruit Count
- 81
- Registration Number
- NCT00372489
- Locations
- πΊπΈ
Research Facility, San Antonio, Texas, United States
Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 22
- Registration Number
- NCT00314795
- Locations
- π¬π§
Research Facility, London, United Kingdom
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Affymax
- Target Recruit Count
- 60
- Registration Number
- NCT00272662
- Locations
- π¬π§
Research Facilities, London, United Kingdom
π΅π±Research Facility, Szczecin, Poland
Peginesatide for Anemia in Chronic Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Affymax
- Target Recruit Count
- 165
- Registration Number
- NCT00228449
- Locations
- πΊπΈ
Research Facility, Norfolk, Virginia, United States
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Affymax
- Target Recruit Count
- 139
- Registration Number
- NCT00228436
- Locations
- π¬π§
Research Facility, Swansea, United Kingdom
π¬π§Research Facilities, London, United Kingdom
Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2005-04-27
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Affymax
- Target Recruit Count
- 17
- Registration Number
- NCT00109291
- Locations
- π¬π§
Research Facility, London, United Kingdom
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Affymax
- Target Recruit Count
- 28
- Registration Number
- NCT00097747
- Locations
- π¬π§
Research Facility, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.